Quantcast

Industry news that matters to you.  Learn more

Archives for March 2012

HTG/Sanofi US Annouce Biomarker Collaboration

HTG Molecular Diagnostics has established a collaborative program with Sanofi US to identify biomarkers that may lead to the development of a molecular companion diagnostic test to help identify patients most likely to respond to a novel Sanofi investigational agent. HTG Molecular Diagnostics’ qNPA technology measures mRNA and/or miRNA expression in formalin fixed paraffin embedded (FFPE) tumor samples, allowing clinicians to verify the presence of certain biomarkers relevant to patient selection and therapy.

Alzheimer’s Association Awards Largest Ever Research Grant to DIAN for Innovative Therapy Trials

The Alzheimer’s Association announced recently the awarding of its largest ever research grant – nearly $4.2 million over four years – to the Dominantly Inherited Alzheimer’s Network–Therapeutic Trials Unit (DIAN-TTU), based at Washington University School of Medicine in St. Louis, to enable the program to move forward more quickly with innovative drug and biomarker trials in people with genetically-based, young-onset Alzheimer’s disease.

Vermillion Receives Notice of Allowance for Patent on Methods for Diagnosing Ovarian Cancer

Vermillion, Inc. (NASDAQ: VRML), a leading molecular diagnostics company, has received a notice of allowance from the United States Patent and Trademark Office for a patent, “Methods for Diagnosing Ovarian Cancer.”

Enterome Raises EUR 5 Million in Series A Funding Round

Enterome, a stratified medicine company developing biomarkers for chronic and challenging medical conditions relating to abnormalities of bacterial composition of the human intestine (metabolic and bowel diseases), today announces a first closing of a series A funding round, raising EUR 5 million. This funding follows a previous seed round that raised EUR 1.5 million from Seventure Partners (Natixis) and INRA Transfert.

Statin Use Appears Associated with Modest Reduction in Parkinson Disease Risk

Regular use of cholesterol-lowering statin drugs may be associated with a modest reduction in risk for developing Parkinson disease, particularly among younger patients, according to a study in the March issue of Archives of Neurology, one of the JAMA/Archives journals.